The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.
Pierre D. Delmas
INSERM Research Unit 831 and University of Lyon
France
Name/email consistency: high
- Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Delmas, P.D., Davis, S.R., Hensen, J., Adami, S., van Os, S., Nijland, E.A. Osteoporos. Int (2008)
- Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Delmas, P.D., McClung, M.R., Zanchetta, J.R., Racewicz, A., Roux, C., Benhamou, C.L., Man, Z., Eusebio, R.A., Beary, J.F., Burgio, D.E., Matzkin, E., Boonen, S. Bone (2008)
- Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Delmas, P.D., Benhamou, C.L., Man, Z., Tlustochowicz, W., Matzkin, E., Eusebio, R., Zanchetta, J., Olszynski, W.P., Recker, R.R., McClung, M.R. Osteoporos. Int (2008)
- Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. Delmas, P.D. J. Clin. Densitom (2008)
- NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women. Delmas, P.D., Siris, E.S. Bone (2008)
- Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. Delmas, P.D., Vrijens, B., Eastell, R., Roux, C., Pols, H.A., Ringe, J.D., Grauer, A., Cahall, D., Watts, N.B. J. Clin. Endocrinol. Metab. (2007)
- Beyond hip: importance of other nonspinal fractures. Delmas, P.D., Marin, F., Marcus, R., Misurski, D.A., Mitlak, B.H. Am. J. Med. (2007)
- Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Delmas, P.D., Licata, A.A., Reginster, J.Y., Crans, G.G., Chen, P., Misurski, D.A., Wagman, R.B., Mitlak, B.H. Bone (2006)
- Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Delmas, P.D., Adami, S., Strugala, C., Stakkestad, J.A., Reginster, J.Y., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M.K., Recker, R.R., Bolognese, M., Hughes, C., Masanauskaite, D., Ward, P., Sambrook, P., Reid, D.M. Arthritis Rheum. (2006)
- Clinical effects of strontium ranelate in women with postmenopausal osteoporosis. Delmas, P.D. Osteoporos. Int (2005)
- Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. Delmas, P.D., van de Langerijt, L., Watts, N.B., Eastell, R., Genant, H., Grauer, A., Cahall, D.L. J. Bone Miner. Res. (2005)
- The use of bisphosphonates in the treatment of osteoporosis. Delmas, P.D. Curr. Opin. Rheumatol (2005)
- Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. Delmas, P.D., Li, Z., Cooper, C. J. Bone Miner. Res. (2004)
- Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Delmas, P.D., Seeman, E. Bone (2004)
- Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Delmas, P.D., Recker, R.R., Chesnut, C.H., Skag, A., Stakkestad, J.A., Emkey, R., Gilbride, J., Schimmer, R.C., Christiansen, C. Osteoporos. Int (2004)
- Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route. Delmas, P.D., Marianowski, L., Perez, A.C., Ribot, C., Pornel, B., Palacios, S., Lopes, P. Maturitas (2004)
- Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Delmas, P.D., Genant, H.K., Crans, G.G., Stock, J.L., Wong, M., Siris, E., Adachi, J.D. Bone (2003)
